Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to VenetoclaxMatthew S. Davids, Yifan Zhai, Asher Chanan‐Khan et al.|Blood|2024Cited by 8